<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67313">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137239</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-177</org_study_id>
    <secondary_id>2013-002090-21</secondary_id>
    <nct_id>NCT02137239</nct_id>
  </id_info>
  <brief_title>Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression</brief_title>
  <official_title>Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the incidence of acute rejection by 6 months in de
      novo renal transplant recipients treated with Belatacept following induction therapy with
      Thymoglobulin, and used in conjunction with adjunct immunosuppression with Mycophenolate
      Mofetil (MMF) or Everolimus and corticosteroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcineurin inhibitor (CNI)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of clinically-suspected biopsy-proven acute rejection (CSBPAR)</measure>
    <time_frame>Up to 6 months post-transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>At 6, 12 and 24 months post-transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of CSBPAR by 12 and 24 months post-transplantation, difference in the incidence of CSBPAR between arms by 6, 12 and 24 months posttransplantation, time to CSBPAR, severity (Banff grades) and treatment (corticosteroids only, T-Cell Depleting Therapies, other) of CSBPAR by 6, 12, and 24 months post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject and graft survival</measure>
    <time_frame>At 6, 12, 24 months post-transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of subjects who survive with a functioning graft at 6, 12 and 24 months post-transplant, proportion of subjects who experience death by 6, 12 and 24 months post-transplant, proportion of subjects who experience graft loss by 6, 12 and 24 months post-transplant, and time to death and graft loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>3, 6, 12 and 24  months post-transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Absolute values and mean changes in calculated glomerular filtration rate (cGFR) by modification of diet in renal disease (study) (MDRD) formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Specific Anti-HLA Antibodies (DSA)</measure>
    <time_frame>Day 1 and by 12 and 24 months post-transplantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence and level of pre-existing and de novo DSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of each treatment regimen</measure>
    <time_frame>Up to 56 days after last dose date (approximate treatment duration 24 months)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of all adverse events (AEs) and serious AEs (SAEs) by 6, 12, and 24 months post-transplantation, incidence of events of special interest (ESI) at 6 months, 12 months, and 24 months, description and incidence of clinically significant changes in vital signs, and description and incidence of laboratory test abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular and metabolic co-morbidities</measure>
    <time_frame>Baseline (Day 1), 6, 12 and 24 months post-transplant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of new onset diabetes after transplant (NODAT) by 6, 12, and 24 months post-transplantation, absolute values and mean change in systolic and diastolic blood pressure from baseline to month 6, month 12 and month 24, absolute values and mean change in lipid parameters from baseline to month 12 and month 24: Total serum cholesterol, high density lipoprotein, low density lipoprotein, and triglycerides</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Arm A: Thymoglobulin+Belatacept+MMF+Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin infusion intravenously, 1.5 mg/kg (on Day 1) and 1 mg/kg per day to reach a total cumulative dose between 4.5 and 5.5 mg/kg
Belatacept infusion intravenously, 10 mg/kg (on Days 1, 7, weeks 2, 4, 8 and 12 post-transplant) and 5 mg/kg every 28 days thereafter until Month 24
MMF between 1.0-2.0 g/day, up to 3.0 g/day for African American/Black subjects at the Investigator's discretion (divided in 2 doses), tablet orally daily for 24 months
Corticosteroids:
Methylprednisolone intravenous infusion in downward tapering doses of 500 mg, 250 mg and 100-150 mg on Days 1 -3 and if needed 60 mg and 30 mg on Days 4-5
Prednisone 30 mg orally Days 4 through 14 and downward taper to 5 mg by Month 3 and downward taper to 2.5 mg by Month 6 through Month 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Thymoglobulin+Belatacept+Everolimus+Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin infusion intravenously, 1.5 mg/kg (on Day 1) and 1 mg/kg per day to reach a total cumulative dose between 4.5 and 5.5 mg/kg
Belatacept infusion intravenously, 10 mg/kg (on Days 1, 7, weeks 2, 4, 8 and 12 post-transplant) and 5 mg/kg every 28 days thereafter until Month 24
Everolimus tablet orally 3 mg/day (1.5 mg twice a day (BID)) starting on Day 3 daily for 24 months
Corticosteroids:
Methylprednisolone intravenous infusion in downward tapering doses of 500 mg, 250 mg and 100-150 mg on Days 1 -3 and if needed 60 mg and 30 mg on Days 4-5
Prednisone 30 mg orally Days 4 through 14 and downward taper to 5 mg by Month 3 and downward taper to 2.5 mg by Month 6 through Month 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Arm A: Thymoglobulin+Belatacept+MMF+Corticosteroids</arm_group_label>
    <arm_group_label>Arm B: Thymoglobulin+Belatacept+Everolimus+Corticosteroids</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <arm_group_label>Arm A: Thymoglobulin+Belatacept+MMF+Corticosteroids</arm_group_label>
    <arm_group_label>Arm B: Thymoglobulin+Belatacept+Everolimus+Corticosteroids</arm_group_label>
    <other_name>Nulojix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
    <arm_group_label>Arm A: Thymoglobulin+Belatacept+MMF+Corticosteroids</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <arm_group_label>Arm A: Thymoglobulin+Belatacept+MMF+Corticosteroids</arm_group_label>
    <arm_group_label>Arm B: Thymoglobulin+Belatacept+Everolimus+Corticosteroids</arm_group_label>
    <other_name>Methylprednisolone</other_name>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Arm B: Thymoglobulin+Belatacept+Everolimus+Corticosteroids</arm_group_label>
    <other_name>Certican®</other_name>
    <other_name>Zortress®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  De Novo Kidney transplant recipients from a non-human leukocyte antigen (HLA)
             identical, living or standard criteria deceased donor

        Exclusion Criteria:

          -  Subjects with Epstein Barr virus (EBV) status negative or unknown

          -  Recipients of extended criteria deceased donor (ECD) kidney
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
